Abstract
Patients with early breast cancer who receive anthracycline-containing chemotherapy experience improved relapse-free (RFS) and overall survival (OS) compared with those who receive non-anthracycline-containing chemotherapy. Such benefit, however, may be restricted to women whose tumors have specific molecular characteristics. We tested the hypothesis that HER2, epidermal growth factor receptor (EGFr)/HER1, HER3, Ki67, and topoisomerase IIalpha expression are predictive of outcome after anthracycline-based chemotherapy.
Original language | English |
---|---|
Pages (from-to) | 5027-35 |
Number of pages | 9 |
Journal | Journal of Clinical Oncology |
Volume | 26 |
Issue number | 31 |
DOIs | |
Publication status | Published - Nov 2008 |
Keywords
- Adult
- Aged
- Antibiotics, Antineoplastic
- Antigens, Neoplasm
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- Chemotherapy, Adjuvant
- Cyclophosphamide
- DNA Topoisomerases, Type II
- DNA-Binding Proteins
- Disease-Free Survival
- Epirubicin
- Female
- Fluorouracil
- Gene Amplification
- Gene Expression Regulation, Neoplastic
- Humans
- Immunohistochemistry
- In Situ Hybridization, Fluorescence
- Ki-67 Antigen
- Methotrexate
- Middle Aged
- Patient Selection
- Receptor Protein-Tyrosine Kinases
- Receptor, Epidermal Growth Factor
- Receptor, erbB-2
- Receptor, erbB-3
- Survival Analysis
- Time Factors
- Tissue Array Analysis
- Treatment Outcome
- Tumor Markers, Biological